Cutting edge news source inspiring health change through knowledge and education

Symptomatic Relief from SIBO with L. salivarius UCC118 Strain

Daily consumption of the probiotic strain Lactobacillus salivarius UCC118 helped relieve severity of gastrointestinal (GI) symptoms associated with small intestinal bacterial overgrowth (SIBO), according to a pilot quality improvement study.

The study participants (n=29) were recruited from patients who presented to the Cleveland Clinic Center for Gut Rehabilitation and Transplantation outpatient clinic (Cleveland, OH). Participants consumed the probiotic strain Lactobacillus salivarius UCC118 in an oral supplement (108 CFU/capsule daily) for 90 days in addition to standard therapy. GI symptoms consistent with SIBO, such as diarrhea, bloating, foul stool, flatulence, and stool characteristics, were assessed at baseline, 30, 60, and 90 days. The data demonstrated that daily consumption of the probiotic strain Lactobacillus salivarius UCC118 was effective in relieving the severity of several GI symptoms and negating or delaying the need for antibiotic therapy.

These results were presented as a scientific poster1 by Gail Cresci, PhD, RD (Cleveland Clinic) at Clinical Nutrition Week 2016 hosted by the American Society for Parenteral and Enteral Nutrition (ASPEN) in Austin, TX.

View the poster

Citation

  1. Cresci G, Izzo K, Furman A, Melnick L, Shantnawei A. Effects of Lactobacillus salivarius UCC118 in reducing symptoms of small intestinal bacterial overgrowth [abstract].

 

 

Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine.
This center of excellence translates credible research with scientific integrity into innovative clinical decision-making.
Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare.

Sponsored by
© 2018 Metagenics Institute. All Rights Reserved